Kevin White
Executive Director - Venture Fund Boehringer Ingelheim
Kevin White is an Investment Manager with the Boehringer Ingelheim Venture Fund, focusing on strategic investments and new company creation across North America. Prior to joining BIVF, he held leadership roles in immunology discovery at AbbVie and spent a decade in the respiratory therapeutic area at Novartis; he completed postdoctoral studies at Harvard Medical School and earned his PhD at the University of Glasgow
Seminars
Wednesday 9th September 2026
Scientific, Operational & Economic Realities for Immune-Modulating Therapies: What Have we Learnt so Far?
11:45 am
- Pharma’s reflections on recent in vivo CAR-T and TCE deals, what data was valuable when clinical data was minimal?
- Overlapping and diverging advantages of TCEs to in vivo CAR-T, including depth and durability of response.
- Debating clinical-adjacent innovations in delivery across viral vectors and LNPs and their application in immunology versus oncology
Thursday 10th September 2026
Investor Icebreaker Panel Discussion: When Being Selective, where will Investors Invest? What’s Driving Capital in 2026/27?
9:30 am
- How are each of the modality landscapes discussed facilitating successful VC exits and what does that mean for the future of investment in these areas?
- How have changes to the barrier to entry for new innovations fed through into investment?
- What will drive or inhibit future investment in these target modalities?
- How to progress discussions with investors. What is expected and helpful to understand from biotech, from the investor perspective?
Thursday 10th September 2026
Investor Introduction Tables: Sit, Connect & Break the Ice: Accelerating Connections
10:00 am
- Starting with a short investor panel introducing investor interests and moving into an organised networking session.
- Mirroring the Pharma Introduction Tables, select the investors that best align with your organisation’s stage and objectives, and join their networking table for 30-minutes. Share business cards or ask a follow-up question from the panel with your target investor to tick off another key connection at the conference.
